Citi keeps a Neutral rating on Iqvia (IQV) with a $160 price target while adding a “downside 90-day short-term view” on the shares. The firm is cautious on Iqvia, citing delayed decision making by customers. The firm sees minimal upside to continued growth in the Technology and Analytics Solutions unit as comps get significantly harder in the second half of the year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- Iqvia price target lowered to $190 from $210 at Mizuho
- Positive Outlook for IQVIA Holdings Driven by Resilient TAS, Strategic Capital Allocation, and R&D Strength
- Definitive Healthcare downgraded to Neutral from Buy at BTIG
- IQVIA Holdings: Strong Performance and Growth Potential Justify Buy Rating
- IQVIA Holdings: Strong Buy Rating Despite R&D Challenges and Valuation Opportunities